Trial Profile
Acceptance of Human Papillomavirus Vaccination in Postpartum Women
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Cervical cancer; Human papillomavirus infections
- Focus Therapeutic Use
- Acronyms HPV Acceptance
- 01 Oct 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 13 Feb 2012 Planned end date changed from 1 Nov 2011 to 1 Oct 2012 as reported by ClinicalTrials.gov.
- 20 Jul 2011 Planned end date changed from 1 Jun 2011 to 1 Nov 2011 as reported by ClinicalTrials.gov.